Foghorn Therapeutics Inc.: management transactions · United States · SEC (Form 4)

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. (ticker: FHTX) is a U.S.-based biotechnology company listed on the NASDAQ market in the United States. For French-speaking investors, Foghorn fits the profile of a next-generation biotech platform rather than a mature commercial pharma company. It is focused on discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system, an area of biology linked to how genes are switched on and off. The company was founded in October 2015 and has built its strategy around its proprietary Gene Traffic Control® platform, which is designed to identify, validate, and exploit novel drug targets in disease areas with significant unmet medical need. Foghorn’s core business is drug discovery and early-to-midstage development, with an emphasis on precision oncology. Its pipeline includes proprietary enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors. Among the most closely watched programs are FHD-909, an oral, selective BRM/SMARCA2 inhibitor, and selective degrader programs targeting CBP, EP300, and ARID1B. The company has also advanced FHD-286, a dual BRG1/BRM-related inhibitor, in specific oncology settings. In other words, Foghorn is not yet a sales-led company; its valuation thesis is driven by the scientific quality of its platform, the progress of its candidates, and the potential for strategic collaborations or clinical milestones. From a competitive standpoint, Foghorn operates in a highly crowded and capital-intensive biotech landscape. Its differentiation lies in the depth of its chromatin biology expertise and the breadth of opportunities that may emerge from one platform. That said, like most development-stage biotech firms, it faces material clinical, regulatory, financing, and execution risks. The opportunity is attractive because the biology is novel and potentially broad, but the path to commercialization remains uncertain. Geographically, the company’s footprint is centered in the United States, with headquarters in Watertown, Massachusetts, near the Boston/Cambridge life-science cluster. Recent company disclosures in 2026 point to continued pipeline momentum and a strengthened balance sheet following a January 2026 equity financing with a group of leading life-science investors. In March 2026, management also provided a financial update and strategic outlook for 2025 and 2026, highlighting ongoing development priorities across FHD-909, CBP, EP300, and ARID1B. For investors in Europe, Foghorn is best viewed as a high-risk, high-upside NASDAQ-listed biotech story anchored in platform innovation, clinical optionality, and long-dated value creation rather than near-term earnings.